On Friday, Shares of Baozun Inc (ADR) (NASDAQ:BZUN), gained 6.13% to $11.08.
Baozun Inc, declared that it has priced its initial public offering of 11,000,000 American depositary shares at US$10.00 per ADS for a total offering size of US$110 million, assuming the underwriters do not exercise their option to purchase additional ADSs. Each ADS represents three Class A ordinary shares of the Company.
The Company has granted the underwriters an option, exercisable within 30 days from the date of the final prospectus, to purchase up to 1,650,000 additional ADSs.
Baozun is the leading brand e-commerce solutions provider in China that assists brand partners execute their e-commerce strategies. The Company’s integrated capabilities encompass all aspects of the e-commerce value chain, covering IT solutions, store operations, digital marketing, customer services, warehousing and fulfillment.
Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), inclined 6.90 % to $ 8.83, during its last trading session.
Inovio Pharmaceuticals, declared that the company has initiated a phase I trial to evaluate safety, tolerability and immune responses of Inovio’s DNA immunotherapy for Ebola. In formerly published preclinical testing, Inovio’s DNA-based Ebola immunotherapy protected 100% of immunized animals from death and sickness after being exposed to a lethal dose of the Ebola virus.
This is the first step in the Inovio-led consortium selected by the U.S. Defense Advanced Research Projects Agency (DARPA) to take a multi-faceted approach to develop products to both prevent and treat Ebola infection. These programs comprise development and early clinical testing of:
- Inovio’s DNA-based vaccine against Ebola, for which the first study was initiated this week.
- Inovio’s therapeutic DNA-based monoclonal antibody product dMAb(TM) against Ebola virus infection. This promising new technology has properties that are best suited to respond to an Ebola outbreak in that they could be designed and manufactured expediently on a large scale using proven fermentation technology, are thermal-stable, and may provide more rapid therapeutic benefit; and
- A highly potent conventional protein-based therapeutic monoclonal antibody (mAb) product against Ebola virus infection.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
At the end of Friday’s trade, Shares of Atlas Resource Partners, L.P. (NYSE:ARP), lost -1.18% to $ 7.51.
Atlas Resource Partners, declared that it has priced an underwritten public offering of 6,500,000 common units representing limited partner interests at an offering price of $7.97 per unit. Wells Fargo Securities, Citigroup, Deutsche Bank Securities, J.P. Morgan and Morgan Stanley are acting as joint book-running managers for this offering. The underwriters have been granted a 30-day option to purchase up to an additional 975,000 common units. The net proceeds of the offering, assuming no exercise of the over-allotment option, after underwriting discounts and estimated expenses, are about $49.5 million.
ARP intends to use a portion of the net proceeds from this offering to fund its declared acquisition of assets in the Arkoma basin in eastern Oklahoma from its parent company, Atlas Energy Group, LLC (ATLS). Proceeds raised in this offering in excess of the purchase price of the Arkoma acquisition are predictable to be used for general partnership purposes, to reduce borrowings outstanding under ARP’s revolving credit facility and for potential future acquisitions.
Atlas Resource Partners, L.P. operates as an independent developer and producer of natural gas, crude oil, and natural gas liquids in the United States. The company operates in three segments: Gas and Oil Production, Well Construction and Completion, and Other Partnership Administration.
Finally, MagneGas Corporation (NASDAQ:MNGA), ended its last trade with 0.00% gained, and closed at $ 1.49.
MagneGas Corporation, declared that a major producer of painting systems, viewed a MagneGas2® demo and has requested an immediate supply of the fuel for metal cutting.
The demo was viewed by company officials on May 19, who indicated they were impressed with the speed and quality of the cut and right away requested a supply of the fuel. The company has locations in the U.S. and Mexico and produces large paint booths and other ancillary systems for the automotive and aerospace manufacturing industries. The gas will initially be supplied to their location in Michigan.
MagneGas Corporation, an alternative energy company, creates and produces hydrogen based alternative fuel through the gasification of carbon-rich liquids in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
